Ticker > Company >

Fredun Pharma share price

Fredun Pharmaceuticals Ltd.

BSE: 539730 SECTOR: Pharmaceuticals & Drugs  15k   40   4

695.40
-7.95 (-1.13%)
BSE: 30 Apr 4:00 PM

Price Summary

Today's High

₹ 705

Today's Low

₹ 694.05

52 Week High

₹ 1024

52 Week Low

₹ 635

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

328.34 Cr.

Enterprise Value

432.5 Cr.

No. of Shares

0.47 Cr.

P/E

17.46

P/B

2.41

Face Value

₹ 10

Div. Yield

0.1 %

Book Value (TTM)

₹  288.47

CASH

1.35 Cr.

DEBT

105.51 Cr.

Promoter Holding

48.93 %

EPS (TTM)

₹  39.82

Sales Growth

26.75%

ROE

15.03 %

ROCE

17.13%

Profit Growth

44.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Fredun Pharmaceuticals Ltd.

MAMALAIT GRANULES FREDCAL BIRD AND BEAUTY PURI5 FREPREIMECAL FREOSSITONE GRANULES FREOSSIPOWER

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year26.75%
3 Year37.51%
5 Year29.12%

Profit Growth

1 Year44.57%
3 Year97.93%
5 Year28.5%

ROE%

1 Year15.03%
3 Year13.44%
5 Year9.96%

ROCE %

1 Year17.13%
3 Year15.97%
5 Year13.56%

Debt/Equity

0.88

Price to Cash Flow

-748.45

Interest Cover Ratio

2.5716

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 48.93 0.00
Dec 2024 48.93 0.00
Sep 2024 48.93 0.00
Jun 2024 49.17 0.00
Mar 2024 49.17 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 97.9346018538067% for the Past 3 years.
  • The company has shown a good revenue growth of 37.510840892994% for the Past 3 years.
  • Company’s PEG ratio is 0.442826719095027.

 Limitations

  • Company has negative cash flow from operations of -0.4387.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 87.01 118.03 78.81 107.35 102.7
Total Expenditure 76.49 106.87 68.33 93.4 89.47
Operating Profit 10.52 11.17 10.48 13.95 13.23
Other Income 0 0 0 0 0
Interest 3.77 4.37 3.91 5.31 5.01
Depreciation 0.99 0.96 1.05 1.06 1.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 5.76 5.84 5.52 7.58 7.14
Tax 1.54 0.78 1.39 3.3 1.8
Profit After Tax 4.22 5.06 4.13 4.27 5.33
Adjusted EPS (Rs) 8.98 10.77 8.79 9.05 11.29

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 112.77 133.89 224.46 274.68 348.16
Total Expenditure 104.44 124.55 210.55 246.9 310.17
Operating Profit 8.33 9.35 13.91 27.78 37.98
Other Income 0.52 1.4 1.63 1.82 0.92
Interest 4.47 4.37 4.78 9.28 13.65
Depreciation 1.88 2 2.16 2.81 3.8
Exceptional Items 0 -1.16 0 0 0
Profit Before Tax 2.49 3.21 8.6 17.51 21.45
Tax 0.59 1.19 2.26 6.7 5.83
Net Profit 1.9 2.01 6.34 10.81 15.62
Adjusted EPS (Rs.) 4.77 5.05 14.29 23.84 33.25

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 3.99 3.99 4.43 4.53 4.7
Total Reserves 37.33 39.08 63.63 91.84 116.77
Borrowings 11.5 29.11 42.04 15.44 12.8
Other N/C liabilities 2.57 2.98 3.14 5.81 6.5
Current liabilities 85.99 86.46 73.75 139.66 166.83
Total Liabilities 141.38 161.62 186.99 257.28 307.6
Assets
Net Block 30.97 30.35 32.34 38.93 46.57
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1.08 1.18 2 2.13 3.36
Other N/C Assets 0 0 0 0 0.46
Current Assets 109.32 130.08 152.65 216.21 257.2
Total Assets 141.38 161.62 186.99 257.28 307.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2.35 2.01 8.58 17.46 21.45
Adjustment 6.03 8.65 7.82 11.7 16.77
Changes in Assets & Liabilities -19.02 -10.5 -18.77 -43.57 -38.66
Tax Paid 0 0 0 0 0
Operating Cash Flow -10.64 0.17 -2.38 -14.41 -0.44
Investing Cash Flow -1.49 -1.39 -4.14 -9.4 -7.64
Financing Cash Flow 13.73 -0.71 7.47 25.18 5.99
Net Cash Flow 1.59 -1.93 0.94 1.36 -2.08

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 49.17 49.17 48.93 48.93 48.93
daulat nariman medhora 30.02 30.02 29.88 29.88 29.88
fredun nariman medhora 3.82 3.82 3.81 3.81 3.81
nariman medhora 15.32 15.32 15.24 15.24 15.24
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 50.83 50.83 51.07 51.07 51.07
arun kumar mukherjee 1.51 1.70 1.43 1.03 1.03
bank of india 1.60 1.60 1.59 1.59 1.59
harsha venkatesh - - - - 1.06
llp 0.51 0.49 0.48 0.41 0.28
nikhil kishorchandra vora... 6.50 6.41 6.38 6.38 6.38

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Fredun Pharmaceuticals secures tender from TNMSC for supply of generic medicines 10 Apr, 2:35 PM Fredun Pharmaceutical informs about press release 3 Apr, 3:13 PM Fredun Pharmaceuticals forays into large animal veterinary segment 12 Mar, 9:44 AM Fredun Pharma - Quaterly Results 4 Feb, 7:59 PM Fredun Pharma - Quaterly Results 4 Feb, 7:59 PM Fredun Pharmaceuticals installs second Italian Tube Filling Machine at production facility 3 Feb, 3:08 PM Fredun Pharmaceuticals launches India’s first dedicated Pet Diagnostic Center 9 Jan, 3:58 PM Fredun Pharma - Quaterly Results 26 Oct, 9:40 PM Fredun Pharma - Quaterly Results 29 Jul, 7:32 PM Fredun Pharma - Quaterly Results 29 Jul, 7:32 PM Fredun Pharma - Quaterly Results 7 May, 10:10 PM Fredun Pharma - Quaterly Results 7 May, 10:10 PM Fredun Pharma - Quaterly Results 14 Feb, 7:24 PM Fredun Pharma - Quaterly Results 14 Feb, 7:24 PM Fredun Pharmaceuticals informs about press release 12 Feb, 1:29 PM Fredun Pharmaceuticals gets orders worth Rs 28 crore from SEA countries 12 Feb, 12:41 PM Fredun Pharmaceuticals informs about voting results of EGM 19 Jan, 5:16 PM Fredun Pharmaceuticals informs about loss of original share certificates 17 Jan, 3:24 PM Fredun Pharmaceuticals informs about board meeting 9 Dec, 2:37 PM Fredun Pharmaceuticals informs about outcome of board meeting 2 Aug, 5:10 PM Fredun Pharmaceuticals informs about press release 21 Jul, 5:08 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharmaceuticals informs about outcome of board meeting 25 May, 9:46 AM Fredun Pharmaceuticals informs about revised outcome of board meeting 3 May, 3:12 PM Fredun Pharmaceuticals informs about outcome of board meeting 28 Jan, 11:50 AM Fredun Pharma - Quaterly Results 27 Jan, 8:10 PM Fredun Pharma - Quaterly Results 27 Jan, 8:10 PM Fredun Pharmaceuticals informs about certificate 3 Jan, 3:07 PM Fredun Pharmaceuticals informs about change in registered office address 13 Dec, 3:07 PM Fredun Pharmaceuticals informs about press release 28 Nov, 5:17 PM Fredun Pharmaceuticals bags two contracts for Pharma and DC Granules 28 Nov, 4:42 PM Fredun Pharma - Quaterly Results 10 Nov, 7:43 PM Fredun Pharma - Quaterly Results 10 Nov, 7:43 PM Fredun Pharma - Quaterly Results 16 May, 7:00 PM Fredun Pharma - Quaterly Results 16 May, 7:00 PM Fredun Pharmaceuticals informs about board meeting 9 May, 10:13 AM Fredun Pharmaceuticals gets nod to manufacture Xenografts 15 Mar, 10:11 AM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharmaceuticals informs about confirmation certificate 4 Oct, 3:40 PM Fredun Pharmaceuticals informs about issue of securities 15 Sep, 5:18 PM Fredun Pharmaceuticals bags order worth Rs 22 crore 15 Sep, 9:16 AM Fredun Pharmaceuticals informs about annual report 6 Sep, 3:55 PM Fredun Pharmaceuticals wins ‘India’s Most Admirable Brand’ award 24 Aug, 10:35 AM Fredun Pharmaceuticals informs about closure of trading window 1 Jul, 1:00 PM Fredun Pharmaceuticals informs about outcome of board meeting 29 Jun, 1:00 PM Fredun Pharmaceuticals board recommends final dividend 29 Jun, 12:54 PM

Fredun Pharma Stock Price Analysis and Quick Research Report. Is Fredun Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Fredun Pharma and its performance over the period of time. Fredun Pharma stock price today is Rs 695.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Fredun Pharma cash from the operating activity was Rs -0.4387 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Fredun Pharma has a Debt to Equity ratio of 0.88 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Fredun Pharma , the EPS growth was 39.438 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Fredun Pharma has OPM of 10.9095572619416 % which is a bad sign for profitability.
     
  • ROE: Fredun Pharma have a average ROE of 15.0262 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Fredun Pharma is Rs 695.4. One can use valuation calculators of ticker to know if Fredun Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Fredun Pharma
X